IMMUNE SYSTEM-DRUG METABOLISM INTERACTIONS: TOXICOLOGICAL INSIGHT

Stanislav G. Yanev

Department Drug Toxicology, Institute of Neurobiology, Bulgarian Academy of Sciences, Sofia, Bulgaria

Abstract

From many years the inflammation is considered as one important determinant of susceptibility to intoxication by xenobiotic exposure. Inflammation and vaccination in most cases are connected with immune system stimulation and release of cytokines, adipokines, reactive oxygen species, nitric oxide, proteases, and lipid metabolites. That was accompanied by different extend of down-regulation of the main xenobiotic/drug metabolizing enzyme system cytochrome P450 (CYP) both in the liver and the adipose tissue. We need more knowledge of possible changes in the pharmacokinetics respectively in effectiveness and side effects of drugs used in chronically ill patients in case of occurrence of acute viral or bacterial infection in them or after the application of different vaccines. This would contribute significantly to the optimization of personal drug therapy avoiding toxicity or lack of effectiveness. Here we tried to summarize some of the main experimental and clinical data of altered drug metabolizing enzyme system in the case of changes in the immune system due to inflammation or vaccination.

Adipobiology 2014; 6: 31-36

Key words: adipose tissue, cytochrome P450, cytokines, interferon, inflammation, toxicity, vaccination

Introduction

Numerous experimental and clinical data suggest that the major system (host defense) that protects humans from infectious organisms interacts with the principal system that affords protection from chemicals including drugs (drug metabolizing enzymes). This interaction has the potential to produce severe and occasionally life-threatening complications in drug therapy during episodes of infectious disease or other pathological changes of immune system. The loss of cytochrome P450 is now considered to be a multifactorial and frequent consequence of *stimulation* of immune system after infection and inflammation (1-6). In most cases that is accompanied with no other signs of toxicity of affected organs (liver, kidney, brain). Few examples exist for cases with reduced inflammation and *immunosuppression* after induction of cytochrome P450: dioxins (CYP 1A1, CYP 2B1)(7), phenobarbital (CYP 2C, CYP 2B, CYP 3A4) (8,9), rifampicin (CYP 3A4)(10), clofibrate and bezafibrate (CYP 4A) (11).

Received 29 November 2014, revised 12 December 2014, accepted 14 December 2014.

Correspondence to Dr Stanislav Yanev, Department Drug Toxicology, Institute of Neurobiology, Bulgarian Academy of Sciences, Acad. G. Bonchev Str., bl. 23, BG-1113 Sofia, Bulgaria. Tel.: +359 2 979 2107, E-mail: tox@bio.bas.bg

Experimental evidences

In animal models, cytochrome P450 is depressed by various types of: (i) bacterial infections - *Listeria monocytogenes* (12), *Actinobacillus pleuropneumoniae* (13), *Chlamydia trachomatis* (14), (ii) viral infection - *Encephalomyocarditis virus* (15), *murine retrovirus LP-BM5* (16), influenza virus (17), (iii) parasitic infections - *Fasciola hepatica* (18), *Plasmodium berghei* (19), and (iv) *Bacillus Calmette-Guerin* (BCG) (20) and *B. pertussis* (21) vaccines.

Likewise, in experimental diseases such as rat adjuvant polyarthritis (22, 23). Of note, 48 hours after the production of an inflammatory reaction generated by the subcutaneous administration of turpentine in rabbit both hind legs, the tolbutamide total body clearance was markedly decreased due to reduced concentration of hepatic cytochrome P450 (24). Acute adenovirus hepatitis in mice resulted in selective down-regulation of acetaminophen (APAP) metabolizing P450s in liver (CYP 1A2 and CYP 2E1), decreased formation of APAP toxic metabolites and thus decreased the risk of APAP hepatotoxicity (25).

The cytochrome P450 down-regulation is time, dose and immune stimulus dependent. It coincides with the maximum immune response in genetically sensitive animals. Inhibition of drug metabolism appeared mainly after stimulation of cellular immunity and interferon production (26).

Clinical evidences

There are many documented examples of compromised drug metabolism in humans with impaired immune system after inflammation (e.g., influenza, adenovirus) or vaccination (27). The magnitude of cytochrome P450 depression in humans is highly variable, and it has been proposed that high initial drug levels may predispose infected individuals to exaggerated pharmacological responses as a result of the down regulation of the drug metabolizing enzymes. These interactions continue to cause problems, such as toxicity, during drug treatment in patients with infections; following vaccination; in cancer patients receiving interferon or cytokine therapy, and in situations where host defense is activated. It is not surprising that the most cases found with impaired drug metabolism after vaccination were patients on chronic anticonvulsant and theophylline treatment where frequent drug monitoring control is obligatory. That concerns incidents of increased carbamazepine (28) and other anticonvulsants toxicity as phenytoin, lorazepam and chlorthalidazepoxide (29-31) few days after immunization. In man, acute viral infections of the upper respiratory tract, bacterial pneumonia and BCG vaccination (see Peter Ghenev's *Dance round* in this volume of *Adipobiology*) are able to reduce the clearance

of theophylline by down-regulating multiple isoforms of the hepatic cytochrome P450. Theophylline plasma levels in bronchitis children increased during influenza epidemics. Quinine blood levels (32) as well as the theophylline plasma half-life (33) were increased during *Plasmodium falciparum malaria* infections. HIV infection was related to an increase in variability of drug metabolizing enzymes (34,35). Patients with rheumatoid arthritis showed a three and four fold higher systemic exposure of verapamil and simvastatin compared to healthy volunteers (36).

Mechanisms of alteration of drug biotransformation during infections and inflammation

When discussing the numerous possible factors responsible for impairment of drug biotransformation and especially of cytochrome P450 system in cases with immunostimulation, it is important to note that (i) the activity and expression of P450 depends on the nature of inflammatory mediators, and (ii) different CYP isoforms are affected to varying degrees by different inflammatory challenge (37).

Mechanisms of cytochrome P450 depression by immunostimulation seems to imply the secretion of pro-inflammatory mediators like cytokines (IL-1, IL-2, IL6, TNF α)(38,39), interferons (α , β , γ) (6), prostaglandin (PG) E1, PGE2, and PGF2 α (40), NF- κ B by immune cells and bacterial endotoxins (LPS), which contribute for decreased CYP protein synthesis through transcriptional suppression and mRNA destabilization (41). Inflammatory mediators down regulate also inducible P450 expression by influencing different intracellular receptors pathways as aryl hydrocarbon receptor (AhR), PPAR α , the constitutive androstane receptor (CAR) and the pregnane X receptor (PXR). Interleukin-6 is most important of them, down-regulates liver CYP3A4 through translational induction of C/EBP β -LIP (liver-enriched transcriptional inhibitory protein), which competes with and antagonizes constitutive C/EBP (enhancer binding proteins) transactivators (39). Gene expression of Cyp3a11 is reduced by activation of Toll-like receptors (TLRs) in mice treated with Gram-negative or Gram-positive bacterial components, LPS or lipoteichoic acid (LTA) respectively (42). Toll-Interleukin 1 Receptor Domain-Containing Adaptor Protein (TIRAP) is involved in TLR2-mediated drug metabolizing enzymes (DME) regulation *in vivo* and in isolated primary hepatocytes, but not in regulation of cytokine expression in the liver (43); for TLR4-resistin interaction, see Gertler's review in this volume of *Adipobiology*. On the other hands the alteration of mouse constitutive CYPs' expression levels during inflammation varies according to the immunostimulation pathway, the anaphylaxis-induced inflammation had less effect than LPS-induced inflammation (44).

With significant importance for safety anticoagulant therapy of millions of patients, were the findings from several control clinical studies, that warfarin kinetics and efficacy were not changed after vaccination with influenza vaccine (45). This findings could be explained with the failure of INF γ to decrease mRNA level of CYP2C cytochromes (main enzymes metabolizing warfarin)(46). Immunostimulants would also activate directly or indirectly (*via* MAF secretion) macrophages or Kupffer cells leading to the secretion of reactive oxygen species (ROS) and NO (47,48) and ultimately to the loss of mRNA^{CYP} (49). In this context there are some experimental evidences that safer immunostimulator should be a drug with some antioxidant properties (50).

Which CYP isoforms are more affected after immune stimulation?

Decreased activities of liver CYP 1A1 (51), 1A2, 2A6, 2B6 and 3A4 are the most affected in infected rats. In humans CYP2A6, CYP2A7, CYP2C19 and CYP3A4 (52) were down-regulated in HBV- and/or HCV-infected livers compared with normal livers. Influenza virus vaccination down regulate CYP 1A2 expression (29). In human immunodeficiency virus-positive patients CYP 2D6 expression was also decreased (53). Some liver enzyme activities as CYP 2E1 and CYP 4A, alcohol dehydrogenase and N-acetyltransferase were even found to be increased (54) and some subfamily (CYP 2B and 3A) to be decreased (55) in AA or LPS treated rats. LPS treatment induced renal CYP 4A mRNAs in mice and rats (thus increased the levels of ω -hydroxylated products of fatty acids) and hepatic CYP4A in rats only (56,57). Increased CYP3A4, CYP3A5, and P-gp mRNA expression levels were also detected in Crohn disease (CD) noninflamed duodenal biopsies which lead to elevated first-pass metabolism of drugs thus explained high inter-individual differences in CD pharmacotherapy (58).

Novel immunotherapeutics and CYP-mediated metabolism

Cytokines or agents known to modulate cytokines should be evaluated in in vivo studies with relevant CYP substrates, particularly when used in combination with small molecules, and most importantly, with small molecules with narrow therapeutic indexes. The same is true for the promising novel anticancer agents that up regulate immune responses. These agents, either alone or in combinations, may cause systemic immune-related adverse events, with potential clinical implications for use of concurrent agents metabolized by CYP and other pathways (59).

Obesity, immune system and drug toxicity

Today, the link between obesity, immunity and inflammation is well documented (60, 61). Likewise, various CYPs were found to be expressed in the adipose tissue which appears to be a “post-liver” major organ involved in the activity of xenobiotic/drug metabolizing enzymes (62-64). Impaired immune response in animals and humans affected by obesity, leading to increased risks of infection. Population studies have shown the same things. For instance, hospitalized patients affected by obesity are more likely to develop secondary infections and complications, such as sepsis, pneumonia, bacteremia, and wound and catheter infections. Overall, it appears that obesity may increase risk for bacterial and viral infections. Mortality of obese patients with severe sepsis was also higher than non-obese patients. In many cases, the basis for these differences is the different degrees of gene expression. Thus, analysis of gene expression in brains of lean and obese mice after intraperitoneal injection with LPS demonstrated more than 10 times differences in lipid transport, insulin receptors and cytochrome P450 enzymes proteins between both groups (65). An important parallel between obesity related pathology of adipose tissue and liver pertains to the emerging role of macrophages (66). It is well known that the phagocytic activity and secretory capacity of Kupffer cells were highly correlate with increased immune reactions and down regulated expression of some liver cytochrome P450's. In the same time the inhibition of Kupffer cell by GdCl₃ (gadolinium chloride) exerted antiobesity effects in high fat-fed mice (67). All this shows that obese persons are not only more susceptible to infections, but with greater risk for adverse drug reactions due to impair drug metabolism and kinetics.

Concurrent inflammation as a determinant of susceptibility to toxicity from xenobiotic agents

Concurrent inflammation should be considered as a potentially important determinant of susceptibility to intoxication from environmental chemicals, drugs and other xenobiotic agents. That is, when exposure to certain xenobiotics coincides with a period of inflammation, an individual may be at greater risk for adverse effects (68).

Conclusion

We need more knowledge of possible changes in the pharmacokinetics respectively in effectiveness and side effects of medicines used in chronically ill patients in case of occurrence of acute viral or bacterial infection in them or after the application of different vaccines. This would contribute significantly to the optimization of personal drug therapy avoiding toxicity or lack of effectiveness.

References

1. Rendic S, Guengerich FP. Update information on drug metabolism systems - 2009, part II: Summary of information on the effects of diseases and environmental factors on human cytochrome P450 (CYP) enzymes and transporters. *Curr Drug Metab* 2010; **11**: 4-84. DOI: 10.2174/138920010791110917
2. Renton KW. Alteration of drug biotransformation and elimination during infection and inflammation. *Pharmacol Ther* 2001; **92**: 147-163. DOI: 10.1016/S0163-7258(01)00165-6
3. Morgan ET, Goralski KB, Piquette-Miller M, Renton KW, Robertson GR, Chaluvadi MR, *et al.* Regulation of drug-metabolizing enzymes and transporters in infection, inflammation, and cancer. *Drug Metab Dispos* 2008; **36**: 205-216. DOI: 10.1124/dmd.107.018747
4. Morgan ET. Regulation of cytochrome p450 by inflammatory mediators: why and how? *Drug Metab Dispos* 2001; **29**: 207-212.
5. Iber H, Sewer MB, Barclay TB, Mitchell SR, Li T, Morgan ET. Modulation of drug metabolism in infectious and inflammatory diseases. *Drug Metab Rev* 1999; **31**: 29-41. DOI: 10.1081/DMR-100101906
6. Christensen H, Hermann M. Immunological response as a source to variability in drug metabolism and transport. *Front Pharmacol* 2012; **3**: 8. DOI: 10.3389/fphar.2012.00008
7. McGrath LF, Georgopoulos P, Gallo MA. Application of a biologically-based RFD estimation method to tetrachlorodibenzo-p-dioxin (TCDD) mediated immune suppression and enzyme induction. *Risk Anal* 1996; **16**: 539-548. DOI: 10.1111/j.1539-6924.1996.tb01099.x
8. Levy FE, Chauvelot-Moachon L, Florentin I, Forest M, Pous C, Fournier C, *et al.* Modification of inflammatory processes by phenobarbital in rats. *Inflammation* 1991; **15**: 471-480. DOI: 10.1007/BF00923344
9. Basta-Kaim A, Budziszewska B, Lason W. Effects of antiepileptic drugs on immune system. *Przegląd Lekarski* 2008; **65**: 799-802.
10. Wang WG, Wang YT, Zhou HL, Li P, Wang G, Gao BS, *et al.* Immunosuppressive effects of Rifampicin on a tuberculosis patient after renal transplant. *Pak J Med Sci* 2011; **27**: 720-722.
11. Amacher DE, Beck R, Schomaker SJ, Kenny CV. Hepatic microsomal enzyme induction, beta-oxidation, and cell proliferation following administration of clofibrate, gemfibrozil, or bezafibrate in the CD rat. *Toxicol.Appl.Pharmacol* 1997; **142**: 143-150. [DOI: 10.1006/taap.1996.8007]
12. Garcia Del Busto CE, Renton KW. Modulation of hepatic cytochrome P450 during *Listeria monocytogenes* infection of the brain. *J Pharm Sci* 2003; **92**: 1860-1868. DOI: 10.1002/jps.10433
13. Monshouwer M, McLellan RA, Delaporte E, Witkamp RF, van Miert AS, Renton KW. Differential effect of pentoxifylline on lipopolysaccharide-induced downregulation of cytochrome P450. *Biochem Pharmacol* 1996; **52**: 1195-1200. DOI: 10.1016/0006-2952(96)00468-6
14. Khatsenko OG, Barteneva NS, de la Maza LM, Kikkawa Y. Role of nitric oxide in the inhibition of cytochrome P450 in the liver of mice infected with *Chlamydia trachomatis*. *Biochem.Pharmacol* 1998; **55**: 1835-1842. DOI: 10.1016/S0006-2952(98)00066-5
15. Singh G, Renton KW. Interferon-mediated depression of cytochrome P-450-dependent drug biotransformation. *Mol Pharmacol* 1981; **20**: 681-684.
16. Ansher S, Thompson W, Watson R. Alterations of hepatic drug metabolism in mice following infection with the murine retrovirus LP-BM5. *Immunopharmacology* 1994; **27**: 215-223. DOI: 10.1016/0162-3109(94)90018-3
17. Mileva M, Tancheva L, Bakalova R, Galabov A, Savov V, Ribarov S. Effect of vitamin E on lipid peroxidation and liver monooxygenase activity in experimental influenza virus infection. *Toxicol Lett* 2000; **114**: 39-45. DOI: 10.1016/S0378-4274(99)00265-9
18. Tsocheva N, Kadiiska M, Yanev S, Poljakova-Krusteva OT, Krustev LP. Changes in some parameters of liver drug metabolism in *Fasciola hepatica* infected and diethylnitrosamine injected rats. *Helminthologia* 1992; **29**: 39-42.
19. De-Oliveira AC, Carvalho RS, Paixao FH, Tavares HS, Gueiros LS, Siqueira CM, *et al.* Up- and down-modulation of liver cytochrome P450 activities and associated events in two murine malaria models. *Malar J* 2010; **9**: 81. DOI: 10.1186/1475-2875-9-81
20. Yanev S, Stoyanov D, Kadiiska M, Stoytchev T, Engibarov E. Biochemical and morphological changes in the liver of guinea pigs treated with Calgevax [abstract]. 4th National Conference on Bacterial Infections and Immunology, Varna, Bulgaria. 1984; p 250.
21. Guencheva G, Yanev S, Koytchev C, Michailova S. Some approaches to additional experimental testing of Pertussis vaccine for toxicity and pharmacological activity. In: Mebele S, Stompe H, Drecher M, editors. pp. 464-479. Berlin Verlag, 1988.
22. Cawthorne MA, Palmer ED, Green J. Adjuvant-induced arthritis and drug-metabolizing enzymes. *Biochem Pharmacol* 1976; **25**: 2683-2688. [DOI: 10.1016/0006-2952(76)90257-4]

23. Kovalev IE, Kosheleva NA, Khlopushina TG, Lysenkova EM, Pautova IG. Inhibition of the cytochrome P-450-dependent monooxygenase system of the liver in rats with adjuvant arthritis. *Patol Fiziol Eksp Ter* 1983; 29-31.
24. Parent C, Belanger PM, Jutras L, du SP. Effect of inflammation on the rabbit hepatic cytochrome P-450 isoenzymes: alterations in the kinetics and dynamics of tolbutamide. *J Pharmacol Exp Ther*. 1992; **261**: 780-787.
25. Getachew Y, James L, Lee WM, Thiele DL, Miller BC. Susceptibility to acetaminophen (APAP) toxicity unexpectedly is decreased during acute viral hepatitis in mice. *Biochem Pharmacol* 2010; **79**: 1363-1371. [DOI: 10.1016/j.bcp.2009.12.019]
26. Williams SJ, Farrell GC. Inhibition of antipyrine metabolism by interferon. *Br J Clin Pharmacol* 1986; **22**: 610-612. DOI: 10.1111/j.1365-2125.1986.tb02943.x
27. Pellegrino P, Clementi E, Capuano A, Radice S. Can vaccines interact with drug metabolism? *Pharmacol Res* 2014; DOI: 10.1016/j.phrs.2014.09.003
28. Robertson WC, Jr. Carbamazepine toxicity after influenza vaccination. *Pediatr Neurol* 2002; **26**: 61-63. DOI: 10.1016/S0887-8994(01)00332-0
29. Meredith CG, Christian CD, Johnson RF, Troxell R, Davis GL, Schenker S. Effects of influenza virus vaccine on hepatic drug metabolism. *Clin Pharmacol Ther*. 1985; **37**: 396-401. DOI: 10.1038/clpt.1985.61
30. Levine M, Jones MW. Toxic reaction to phenytoin following a viral infection. *Can Med Assoc J* 1983; **128**: 1270-1271.
31. Jann MW, Fidone GS. Effect of influenza vaccine on serum anticonvulsant concentrations. *Clin Pharm*. 1986; **5**: 817-820.
32. Sowunmi A. Disposition of oral quinine in African patients suffering from acute uncomplicated falciparum malaria. *East Afr Med J* 1996; **73**: 519-523.
33. Akinyinka OO, Sowunmi A, Honeywell R, Renwick AG. The effects of acute falciparum malaria on the disposition of caffeine and the comparison of saliva and plasma-derived pharmacokinetic parameters in adult Nigerians. *Eur J Clin Pharmacol* 2000; **56**: 159-165. DOI: 10.1007/s002280050735
34. Jones AE, Brown KC, Werner RE, Gotzkowsky K, Gaedigk A, Blake M, *et al*. Variability in drug metabolizing enzyme activity in HIV-infected patients. *Eur J Clin Pharmacol* 2010; **66**: 475-485. DOI: 10.1007/s00228-009-0777-6
35. Slain D, Pakyz A, Israel DS, Monroe S, Polk RE. Variability in activity of hepatic CYP3A4 in patients infected with HIV. *Pharmacotherapy* 2000; **20**: 898-907. DOI: 10.1592/phco.20.11.898.35262
36. Mayo PR, Skeith K, Russell AS, Jamali F. Decreased dromotropic response to verapamil despite pronounced increased drug concentration in rheumatoid arthritis. *Br J Clin Pharmacol* 2000; **50**: 605-613. DOI: 10.1046/j.1365-2125.2000.00314.x
37. Bleau AM, Fradette C, El-Kadi AO, Cote MC, *et al*. Cytochrome P450 down-regulation by serum from humans with a viral infection and from rabbits with an inflammatory reaction. *Drug Metab Dispos* 2001; **29**: 1007-1012.
38. Tinel M, Elkahwaji J, Robin MA, Fardel N, Descatoire V, Haouzi D, *et al*. Interleukin-2 overexpresses c-myc and down-regulates cytochrome P-450 in rat hepatocytes. *J Pharmacol Exp Ther* 1999; **289**: 649-655.
39. Jover R, Bort R, Gomez-Lechon MJ, Castell JV. Down-regulation of human CYP3A4 by the inflammatory signal interleukin-6: molecular mechanism and transcription factors involved. *FASEB J* 2002; **16**: 1799-1801. [DOI: 10.1096/fj.02-0195fje]
40. Ishizuki S, Kanda N, Fujihira E. Prostaglandins: a possible mediator to inhibit hepatic drug metabolism in adjuvant arthritic rats. *Biochem Med Metab Biol*. 1986; **35**: 40-49. [DOI: 10.1016/0885-4505(86)90056-3]
41. Delaporte E, Renton KW. Cytochrome P4501A1 and cytochrome P4501A2 are downregulated at both transcriptional and post-transcriptional levels by conditions resulting in interferon-alpha/beta induction. *Life Sci* 1997; **60**: 787-796. [DOI: 10.1016/S0024-3205(97)00006-4]
42. Gandhi AS, Guo T, Shah P, Moorthy B, Chow DS, Hu M, *et al*. CYP3A-dependent drug metabolism is reduced in bacterial inflammation in mice. *Br J Pharmacol* 2012; **166**: 2176-2187. DOI: 10.1111/j.1476-5381.2012.01933.x
43. Ghose R, Guo T, Vallejo JG, Gandhi A. Differential role of Toll-interleukin 1 receptor domain-containing adaptor protein in Toll-like receptor 2-mediated regulation of gene expression of hepatic cytokines and drug-metabolizing enzymes. *Drug Metab Dispos*. 2011; **39**: 874-881. DOI: 10.1124/dmd.110.037382
44. Moriya N, Kataoka H, Fujino H, Nishikawa J, Kugawa F. Different expression patterns of hepatic cytochrome P450 s during anaphylactic or lipopolysaccharide-induced inflammation. *Pharmazie* 2014; **69**: 142-147.
45. Jackson ML, Nelson JC, Chen RT, Davis RL, Jackson LA. Vaccines and changes in coagulation parameters in adults on chronic warfarin therapy: a cohort study. *Pharmacoepidemiol Drug Saf* 2007; **16**: 790-796. DOI: 10.1002/pds.1386
46. Aitken AE, Morgan ET. Gene-specific effects of inflammatory cytokines on cytochrome P450 2C, 2B6 and 3A4 mRNA levels in human hepatocytes. *Drug Metab Dispos* 2007; **35**: 1687-1693. DOI: 10.1124/dmd.107.015511

47. Ferrari L, Peng N, Halpert JR, Morgan ET. Role of nitric oxide in down-regulation of CYP2B1 protein, but not RNA, in primary cultures of rat hepatocytes. *Mol Pharmacol* 2001; 60: 209-216.
48. Kitaichi K, Wang L, Takagi K, Iwase M, Shibata E, Nadai M, *et al.* Decreased antipyrine clearance following endotoxin administration: in vivo evidence of the role of nitric oxide. *Antimicrob Agents Chemother* 1999; 43: 2697-2701.
49. Kim TH, Lee SH, Lee SM. Role of Kupffer cells in pathogenesis of sepsis-induced drug metabolizing dysfunction. *FEBS J* 2011; 278: 2307-2317. DOI: 10.1111/j.1742-4658.2011.08148.x
50. Yanev S, Zidek Z, Kadiiska M, Serbinova E, Masek K, Stoytchev T. Hepatic mixed-function oxidase system and microsomal lipid peroxidation in rats treated with a synthetic immunomodulator, N-acetylmuramyl-L-alanyl-D-isoglutamine (MDP). *Methods Find Exp Clin Pharmacol* 1984; 6: 311-315.
51. Paton TE, Renton KW. Cytokine-mediated down-regulation of CYP1A1 in Hepa1 cells. *Biochem Pharmacol* 1998; 55: 1791-1796. [DOI: 10.1016/S0006-2952(98)00028-8]
52. Li S, Hu ZH, Miao XH. Effects of chronic HBV infection on human hepatic cytochrome P450 3A4. *Zhonghua Yi Xue Za Zhi* 2006; 86: 2703-2706.
53. O'Neil WM, Gilfix BM, Markoglou N, Di GA, Tsoukas CM, Wainer IW. Genotype and phenotype of cytochrome P450 2D6 in human immunodeficiency virus-positive patients and patients with acquired immunodeficiency syndrome. *Eur J Clin Pharmacol* 2000; 56: 231-240. DOI: 10.1007/s002280000116
54. Zidek Z, Janku I. Increased acetylation and elimination of sulphadimidine in rats with adjuvant induced arthritis. *Eur J Drug Metab Pharmacokinet* 1981; 6: 255-259.
55. Sanada H, Sekimoto M, Kamoshita A, Degawa M. Changes in expression of hepatic cytochrome P450 subfamily enzymes during development of adjuvant-induced arthritis in rats. *J Toxicol Sci* 2011; 36: 181-190. DOI: 10.2131/jts.36.181
56. Sewer MB, Koop DR, Morgan ET. Differential inductive and suppressive effects of endotoxin and particulate irritants on hepatic and renal cytochrome P-450 expression. *J Pharmacol Exp Ther* 1997; 280: 1445-1454.
57. Morgan ET. Regulation of cytochromes P450 during inflammation and infection. *Drug Metab Rev* 1997; 29: 1129-1188. DOI: 10.3109/03602539709002246
58. Fakhoury M, Lecordier J, Medard Y, Peuchmaur M, Jacqz-Agrain E. Impact of inflammation on the duodenal mRNA expression of CYP3A and P-glycoprotein in children with Crohn's disease. *Inflamm Bowel Dis* 2006; 12: 745-749. DOI: 10.1097/00054725-200608000-00011
59. Harvey RD, Morgan ET. Cancer, inflammation, and therapy: effects on cytochrome p450-mediated drug metabolism and implications for novel immunotherapeutic agents. *Clin Pharmacol Ther* 2014; 96: 449-457. DOI: 10.1038/clpt.2014.143
60. Karagiannides I, Pothoulakis C. Obesity, innate immunity and gut inflammation. *Curr Opin Gastroenterol* 2007; 23:661-666.
61. Seijkens T, Kusters P, Chatzigeorgiou A, Chavakis T, Lutgens E. Immune cell crosstalk in obesity: a key role for costimulation? *Diabetes* 2014; 63:3982-3991. DOI: 10.2337/db14-0272.
62. Ellero S, Chakhtoura G, Barreau C, Langouet S, Benelli C, Penicaud L, *et al.* Xenobiotic-metabolizing cytochromes P450 in human white adipose tissue: expression and induction. *Drug Metab Dispos* 2010; 38: 679-686.
63. Yanev S, Chaldakov GN. Adipotoxicology of obesity and related disease. *Biomed Rev* 2012; 23: 53-60.
64. La Merrill M, Emond C, Kim MJ, Antignac J-P, Le Bizec B, Clément K, *et al.* Toxicological function of adipose tissue: Focus on persistent organic pollutants. *Environ Health Perspect* 2013; 121:162-169. <http://dx.doi.org/10.1289/ehp.1205485>
65. Scott LK, Vachharajani V, Mynatt RL, Minagar A, Conrad SA. Brain RNA expression in obese vs lean mice after LPS-induced systemic inflammation. *Front Biosci* 2004; 9: 2686-2696. DOI: dx.doi.org/10.2741/1428
66. Federico A, D'Aiuto E, Borriello F, Barra G, Gravina AG, Romano M, *et al.* Fat: a matter of disturbance for the immune system. *World J Gastroenterol* 2010; 16: 4762-4772. DOI: 10.3748/wjg.v16.i38.4762
67. Neyrinck AM, Cani PD, Dewulf EM, De Backer F, Bindels LB, Delzenne NM. Critical role of Kupffer cells in the management of diet-induced diabetes and obesity. *Biochem Biophys Res Commun* 2009; 385: 351-356. DOI: 10.1016/j.bbrc.2009.05.070
68. Ganey PE, Roth RA. Concurrent inflammation as a determinant of susceptibility to toxicity from xenobiotic agents. *Toxicology* 2001; 169: 195-208. DOI: 10.1016/S0300-483X(01)00523-6